Inclisiran Reduced LDL-C in Obese Patients | DAIC
Inclisiran: First Approval | SpringerLink
Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials
ESC 2019 – Medicines Company impresses with inclisiran | Evaluate
Estimation of the major cardiovascular events prevention with Inclisiran - ScienceDirect
Frontiers | PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects | Physiology
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis | Journal of the American College of Cardiology
FAQ — ORION 4
AHA 2019 – The Medicines Company reaches for the stars | Evaluate
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender | Novartis
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
AHA 2019 – The Medicines Company reaches for the stars | Evaluate
Dr. Martha Gulati “Get Vaccinated Please” på Twitter: "Clinical trials Phase III on ORION: Inclisiran vs placebo: 55% LDL reduction on top of lipid lowering therapy #ACC20 https://t.co/mhgNXuKyiJ" / Twitter
ORION-4 — Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU)
Two-Dose a Year LDL-lowering Drug Had Significant Impact in Pooled Analysis of ORION Trials | DAIC
The Medicines Company: Limited Upside And A Tough Market Battle For Inclisiran (NASDAQ:MDCO) | Seeking Alpha
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol | NEJM
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
Diseases | Free Full-Text | Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia | HTML
Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug's Approval | tctmd.com
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender | Novartis
The Medicines Company: Limited Upside And A Tough Market Battle For Inclisiran (NASDAQ:MDCO) | Seeking Alpha
RNAi Inclisiran A Novel Approach to PCSK 9
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia | NEJM
ORION-1 Inclisiran inhibits PCSK9 synthesis by RNA interference Planned interim analysis of a multi-center randomized controlled dose-finding trial Kausik. - ppt download
Abstract 13503: Relative Efficacy of Alirocumab, Bempedoic Acid, Evolocumab, Ezetimibe and Inclisiran Added to Statins for Reduction of Low Density Lipoprotein Cholesterol - A Network Meta-Analysis of Randomized Clinical Trials | Circulation
Leqvio (inclisiran) for the Treatment of Hypercholaesterolemia
